PMID- 17388708
OWN - NLM
STAT- MEDLINE
DCOM- 20070403
LR  - 20220316
IS  - 1555-2101 (Electronic)
IS  - 0160-6689 (Linking)
VI  - 68
IP  - 3
DP  - 2007 Mar
TI  - Atomoxetine in the treatment of binge-eating disorder: a randomized 
      placebo-controlled trial.
PG  - 390-8
AB  - OBJECTIVE: Binge-eating disorder (BED) is associated with obesity. Atomoxetine is 
      a highly selective norepinephrine reuptake inhibitor associated with weight loss. 
      The purpose of this study was to evaluate atomoxetine in the treatment of BED. 
      METHOD: In this 10-week, single-center, randomized, double-blind, 
      placebo-controlled, flexible dose (40-120 mg/day) trial, outpatients with 
      DSM-IV-TR BED received atomoxetine or placebo. The primary outcome measure was 
      binge-eating episode frequency. The primary analysis of efficacy was a 
      longitudinal analysis of the intent-to-treat sample, with treatment-by-time 
      interaction as the effect measure. Patients were enrolled from September 2004 
      through October 2005. RESULTS: Compared with placebo (N = 20), atomoxetine (N = 
      20) was associated with a significantly greater rate of reduction in binge-eating 
      episode frequency, as well as in binge day frequency, weight, body mass index, 
      and scores on the Clinical Global Impressions-Severity of Illness scale, 
      Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating obsession 
      sub-scale, and Three Factor Eating Questionnaire hunger subscale. The mean (SD) 
      atomoxetine daily dose at endpoint evaluation was 106 (21) mg/day. Four patients 
      (N = 3 receiving atomoxe-tine, N = 1 receiving placebo) discontinued because of 
      adverse events. The reasons for atomoxetine discontinuation were increased 
      depressive symptoms (N = 1), constipation (N = 1), and nervousness (N = 1). 
      CONCLUSION: Atomoxetine was efficacious and fairly well tolerated in the 
      short-term treatment of BED. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov 
      identifier NCT00327834.
FAU - McElroy, Susan L
AU  - McElroy SL
AD  - Psychopharmacology Research Program, Department of Psychiatry, University of 
      Cincinnati College of Medicine, OH 45267-0559, USA. susan.mcelroy@uc.edu
FAU - Guerdjikova, Anna
AU  - Guerdjikova A
FAU - Kotwal, Renu
AU  - Kotwal R
FAU - Welge, Jeffrey A
AU  - Welge JA
FAU - Nelson, Erik B
AU  - Nelson EB
FAU - Lake, Kathleen A
AU  - Lake KA
FAU - Keck, Paul E Jr
AU  - Keck PE Jr
FAU - Hudson, James I
AU  - Hudson JI
LA  - eng
SI  - ClinicalTrials.gov/NCT00327834
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Psychiatry
JT  - The Journal of clinical psychiatry
JID - 7801243
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Propylamines)
RN  - 57WVB6I2W0 (Atomoxetine Hydrochloride)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/adverse effects/*therapeutic use
MH  - Adult
MH  - Atomoxetine Hydrochloride
MH  - Body Mass Index
MH  - Body Weight
MH  - Bulimia Nervosa/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propylamines/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2007/03/29 09:00
MHDA- 2007/04/04 09:00
CRDT- 2007/03/29 09:00
PHST- 2007/03/29 09:00 [pubmed]
PHST- 2007/04/04 09:00 [medline]
PHST- 2007/03/29 09:00 [entrez]
AID - 10.4088/jcp.v68n0306 [doi]
PST - ppublish
SO  - J Clin Psychiatry. 2007 Mar;68(3):390-8. doi: 10.4088/jcp.v68n0306.